Skip to main content
Clinical Trials/SLCTR/2015/031
SLCTR/2015/031
Withdrawn
Phase 3

A randomised clinical trial on the efficacy of intravenous N-acetylcysteine compared to oral N-acetylcysteine and oral methionine in reducing liver cell injury in paracetamol (acetaminophen) poisoning

South Asian Clinical Toxicology Research Collaboration (SACTRC)0 sitesTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
iver cell injury in acetaminophen overdose.
Sponsor
South Asian Clinical Toxicology Research Collaboration (SACTRC)
Status
Withdrawn
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
South Asian Clinical Toxicology Research Collaboration (SACTRC)

Eligibility Criteria

Inclusion Criteria

  • 1\. Age 16 years and above
  • 2\. All patients who have taken a paracetamol overdose (\>200mg/kg) where the physician determines an antidote is to be administered

Exclusion Criteria

  • 1\. Patients presenting 24 hours or more after poisoning.
  • 2\. Patients who have already received an antidote (possible in other hospitals prior to transfer).
  • 3\. Patients who have received charcoal (which would interfere with oral antidotes).
  • 4\. Patients under the age of 16\.
  • 5\. Patients who are institutionalized for any mental health condition.
  • 6\. Patients with known cognitive impairment (e.g. dementia).
  • 7\. Patients with unrelated life threatening illness (e.g. terminal cancer).
  • 8\. Patients who are pregnant.
  • 9\. Patients who have had a paracetamol overdose in the previous 4 weeks or have taken a significant dose of any other toxic substance in addition to paracetamol.
  • 10\. Patients who are on warfarin.

Outcomes

Primary Outcomes

Not specified

Similar Trials